No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis

被引：180
|
作者：
Strober, B. E. [1 ,2 ]
Langley, R. G. B. [3 ]
Menter, A. [4 ]
Magid, M. [5 ]
Porter, B. [6 ]
Fox, T. [7 ]
Safi, J., Jr. [6 ]
Papavassilis, C. [7 ]
机构：
[1] Univ Connecticut, Ctr Hlth, Dept Dermatol, Farmington, CT 06030 USA
[2] Prob Med Res, Waterloo, ON, Canada
[3] Dalhousie Univ, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada
[4] Baylor Univ, Med Ctr, Div Dermatol, Dallas, TX USA
[5] UT Austin, Seton Family Hosp, Dept Psychiat, Austin, TX USA
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Novartis Pharma AG, Basel, Switzerland
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2018年 / 178卷 / 02期
关键词：
POPULATION-BASED-COHORT;
D O I：
10.1111/bjd.16051
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E105 / E107
页数：3
相关论文
共 50 条
  • [21] Efficacy and safety of secukinumab by age group in patients with moderate-to-severe plaque psoriasis: Pooled analysis of 4 phase III trials
    Draelos, Zoe
    Kempers, Steven
    Helfrich, Yolanda
    Meng, Xiangyi
    Fox, Todd
    Nyirady, Judit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB247 - AB247
  • [22] Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
    Sandra Adsit
    Enrique Rivas Zaldivar
    Howard Sofen
    Ignacio Dei-Cas
    César Maldonado-García
    Elkin O. Peñaranda
    Luís Puig
    Xiangyi Meng
    Todd Fox
    Adriana Guana
    Advances in Therapy, 2017, 34 : 1772 - 1772
  • [23] Safety of tildrakizumab for moderate-to-severe chronic plaque psoriasis: Pooled analysis of three randomized controlled studies
    Blauvelt, Andrew
    Reich, Kristian
    Papp, Kim A.
    Kimball, Alexa B.
    Gooderham, Melinda
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Li, Qing
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB252 - AB252
  • [24] Secukinumab was efficacious across body regions affected by moderate to severe plaque psoriasis: Pooled analysis of phase III studies
    Menter, Alan
    Cather, Jennifer
    Jarratt, Michael
    Meng, Xiangyi
    Guana, Andriana
    Nyirady, Judit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB251 - AB251
  • [25] Secukinumab was efficacious in the treatment of moderate to severe plaque psoriasis in the North American population: Pooled analysis of phase III studies
    Pariser, David
    Frankel, Ellen
    Schlessinger, Joel
    Meng, Xiangyi
    Guana, Adriana
    Nyirady, Judit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB251 - AB251
  • [26] Secukinumab is efficacious in the treatment of moderate to severe plaque psoriasis regardless of sex of subjects: Pooled analysis from four phase 3 studies
    Spelman, L.
    Griffiths, C.
    Gong, Y.
    Fox, T.
    Papavassilis, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 74 - 75
  • [27] Maintenance regimen of secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the OPTIMISE study
    Reich, Kristian
    Puig, Lluis
    Szepietowski, Jacek C.
    Paul, Carle
    Lacour, Jean Philippe
    Tsianakas, Athanasios
    Sieder, Christian
    Rissler, Michael
    Jagiello, Piotr
    Orsenigo, Roberto
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB90 - AB90
  • [28] Secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the Efficacy of Response and Safety of 2 fixed secUkinumab REgimens in psoriasis (ERASURE)
    Elewski, B.
    Lebwohl, M.
    Papp, K.
    Nakagawa, H.
    Sigurgeirsson, B.
    Tsai, T. -F.
    Tyring, S.
    Hampele, I.
    Karpov, A.
    Helou, S.
    Papavassilis, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 : 43 - 43
  • [29] Secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the Efficacy of Response And Safety of 2 fixed secUkinumab REgimens in psoriasis (ERASURE)
    Elewski, B.
    Lebwohl, M.
    Papp, K.
    Nakagawa, H.
    Sigurgeirsson, B.
    Tsai, T.
    Tyring, S.
    Hampele, I.
    Karpov, A.
    Helou, S.
    Papavassilis, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 15 - 15
  • [30] Secukinumab in moderate-to-severe plaque psoriasis: Results from the Secukinumab Trial Analyzing the potential of intravenous administration To Upgrade the REsponse in psoriasis (STATURE)
    Thaci, D.
    Humeniuk, J.
    Frambach, Y.
    Bissonnette, R.
    Goodman, J.
    Shevadeb, S.
    Gong, Y.
    Helou, S.
    Papavassilis, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 13 - 13
12345